The objective of this study was to characterize cervicovaginal (CV) mucosal factors modulating susceptibility to human immunodeficiency virus (HIV) acquisition in healthy premenopausal (PRE) and postmenopausal (POST) women before and after treatment with estradiol (E2). We compared CV mucosal epithelial histology and immune cells, vaginal microbiota, antimicrobial activity of and soluble mucosal protein concentrations in the CV fluid lavage (CVL), and p24 antigen production after ex vivo infection of ectocervical tissues with HIV-1BaL among PRE women (n = 20) in the follicular and luteal phases of the menstrual cycle and POST women (n = 17) at baseline and after ∼1 month of treatment with 0.01% vaginal E2 cream. Compared to PRE women, we measured higher levels of p24 antigen after ex vivo infection in tissues from POST women. POST women had a significantly thinner vaginal epithelium with decreased tight junction proteins and a higher density of mucosal immune T cells and lower levels of CD1a antigen-presenting cells, antimicrobial peptides, and inflammatory cytokines in the CVL (p values <.05). POST women had higher vaginal pH and lower vaginal Lactobacilli (p values <.05) than PRE women. After vaginal E2 therapy, CV endpoints and ex vivo HIV replication in POST tissues were similar to those observed in PRE tissues. The CV mucosa in POST women is thinned and compromised, with increased HIV-target immune cells and decreased antimicrobial factors, being more susceptible to HIV infection. After POST women receive topical E2 treatment, mucosal endpoints are similar to PRE levels.
Get full access to this article
View all access options for this article.
References
1.
UNAIDS: The gap report. Available at www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf (2014), accessed May4, 2017.
2.
SperoffL, GlassRH, KaseNG: Steroid metabolism. In: Clinical Endocrinology and Infertility, Vol 4th (SperoffL, ed.) Philadelphia, PA: Lippincott Williams and Wilkins, 1989, p. 629.
3.
Centers for Disease Control and Prevention: HIV surveillance report 2014. Available at www.cdc.gov/hiv/library/reports/surveillance/ (2014), accessed May4, 2017.
4.
DwyerJM, PennyR, GatenbyPA, LearmontJ: Susceptibility of postmenopausal women to infection with HIV during vaginal intercourse. Med J Aust, 1990; 153:299.
5.
HIV ESGoHTo: Comparison of female to male and male to female transmission of HIV in 563 stable couples. European Study Group on heterosexual transmission of HIV. BMJ, 1992; 304:809–813.
6.
AabyP, AriyoshiK, BucknerM, et al.: Age of wife as a major determinant of male-to-female transmission of HIV-2 infection: A community study from rural West Africa. AIDS, 1996; 10:1585–1590.
7.
DorganJF, BaerDJ, AlbertPS, et al.: Serum hormones and the alcohol-breast cancer association in postmenopausal women. J Natl Cancer Inst, 2001; 93:710–715.
8.
LeroyV, Van de PerreP, LepageP, et al.: Seroincidence of HIV-1 infection in African women of reproductive age: A prospective cohort study in Kigali, Rwanda, 1988–1992. AIDS, 1994; 8:983–986.
9.
TahaTE, DallabettaGA, HooverDR, et al.: Trends of HIV-1 and sexually transmitted diseases among pregnant and postpartum women in urban Malawi. AIDS, 1998; 12:197–203.
10.
GrayRH, LiX, KigoziG, et al.: Increased risk of incident HIV during pregnancy in Rakai, Uganda: A prospective study. Lancet, 2005; 366:1182–1188.
ClarkMK, SowersM, LevyBT, TenhundfeldP: Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. Fertil Steril, 2001; 75:871–877.
13.
OrtizA, HirolM, StanczykFZ, GoebelsmannU, MishellDR: Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab, 1977; 44:32–38.
14.
PolisCB, CurtisKM, HannafordPC, et al.: Update on hormonal contraceptive methods and risk of HIV acquisition in women: A systematic review of epidemiological evidence, 2016. AIDS, 2016; 30:2665–2683.
15.
NugentRP, KrohnMA, HillierSL: Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol, 1991; 29:297–301.
16.
ThurmanAR, KimbleT, HeroldB, et al.: Bacterial vaginosis and subclinical markers of genital tract inflammation and mucosal immunity. AIDS Res Hum Retroviruses, 2015; 31:1139–1152.
17.
KellerMJ, MadanRP, TorresNM, et al.: A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One, 2011; 6:e16475.
18.
MurphyK, RichardsonBA, DezzuttiCS, et al.: Levels of genital tract defensins and cytokines differ between HIV-uninfected US and African women. Am J Reprod Immunol, 2015; 74:313–322.
19.
ChandraN, ThurmanAR, AndersonS, et al.: Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues. AIDS Res Hum Retroviruses, 2013; 29:592–601.
20.
ThurmanAR, ChandraN, YousefiehN, et al.: Comparison of follicular and luteal phase mucosal markers of HIV susceptibility in healthy women. AIDS Res Hum Retroviruses, 2016; 32:547–560.
21.
Richardson-HarmanN, MauckC, McGowanI, AntonP: Dose–response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study. AIDS Res Hum Retroviruses, 2012; 28:1422–1433.
22.
Richardson-HarmanN, Lackman-SmithC, FletcherPS, et al.: Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. J Clin Microbiol, 2009; 47:3530–3539.
23.
Richardson-HarmanN, HendrixCW, BumpusNN, et al.: Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study. PLoS One, 2014; 9:e111507.
24.
RollenhagenC, AsinSN: Enhanced HIV-1 replication in ex vivo ectocervical tissues from post-menopausal women correlates with increased inflammatory responses. Mucosal Immunol, 2011; 4:671–681.
25.
YeamanGR, WhiteHD, HowellA, PrabhalaR, WiraCR: The mucosal immune system in the human female reproductive tract: Potential insights into the heterosexual transmission of HIV. AIDS Res Hum Retroviruses, 1998; 14Suppl 1:S57–S62.
26.
SabaE, GrivelJC, VanpouilleC, et al.: HIV-1 sexual transmission: Early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal Immunol, 2010; 3:280–290.
27.
VeazeyRS, ThamIC, MansfieldKG, et al.: Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: Highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. J Virol, 2000; 74:57–64.
28.
MooreAC, BixlerSL, LewisMG, VerthelyiD, MattapallilJJ: Mucosal and peripheral Lin- HLA-DR+ CD11c/123− CD13+ CD14− mononuclear cells are preferentially infected during acute simian immunodeficiency virus infection. J Virol, 2012; 86:1069–1078.
29.
JaspanHB, LiebenbergL, HanekomW, et al.: Immune activation in the female genital tract during HIV infection predicts mucosal CD4 depletion and HIV shedding. J Infect Dis, 2011; 204:1550–1556.
30.
BhoopatL, EianglengL, RugpaoS, et al.: In vivo identification of Langerhans and related dendritic cells infected with HIV-1 subtype E in vaginal mucosa of asymptomatic patients. Mod Pathol, 2001; 14:1263–1269.
31.
AhmedSM, Al-DoujailyH, JohnsonMA, KitchenV, ReidWM, PoulterLW: Immunity in the female lower genital tract and the impact of HIV infection. Scand J Immunol, 2001; 54:225–238.
32.
MeditzAL, MoreauKL, MaWhinneyS, et al.: CCR5 expression is elevated on endocervical CD4+ T cells in healthy postmenopausal women. J Acquir Immune Defic Syndr, 2012; 59:221–228.
33.
MesquitaPM, CheshenkoN, WilsonSS, et al.: Disruption of tight junctions by cellulose sulfate facilitates HIV infection: Model of microbicide safety. J Infect Dis, 2009; 200:599–608.
34.
InoueM, OgawaH, MiyataM, ShiozakiH, TanizawaO: Expression of E-cadherin in normal, benign, and malignant tissues of female genital organs. Am J Clin Pathol, 1992; 98:76–80.
35.
KaushicC, NazliA, FerreiraVH, KafkaJK: Primary human epithelial cell culture system for studying interactions between female upper genital tract and sexually transmitted viruses, HSV-2 and HIV-1. Methods, 2011; 55:114–121.
36.
SankapalS, GuptaP, RatnerD, et al.: HIV Exposure to the epithelia in ectocervical and colon tissues induces inflammatory cytokines without tight junction disruption. AIDS Res Hum Retroviruses, 2016; 32:1054–1066.
37.
MolanderU, MilsomI, EkelundP, MellstromD, ErikssonO: Effect of oral oestriol on vaginal flora and cytology and urogenital symptoms in the post-menopause. Maturitas, 1990; 12:113–120.
38.
GuptaS, KumarN, SinghalN, ManektalaU, JainS, SodhaniP: Cytohormonal and morphological alterations in cervicovaginal smears of postmenopausal women on hormone replacement therapy. Diagn Cytopathol, 2006; 34:676–681.
39.
SomeyaM, KojimaT, OgawaM, et al.: Regulation of tight junctions by sex hormones in normal human endometrial epithelial cells and uterus cancer cell line Sawano. Cell Tissue Res, 2013; 354:481–494.
Pellett MadanR, MassonL, TugetmanJ, et al.: Innate antibacterial activity in female genital tract secretions is associated with increased risk of HIV acquisition. AIDS Res Hum Retroviruses, 2015; 31:1153–1159.
42.
BebellLM, PassmoreJA, WilliamsonC, et al.: Relationship between levels of inflammatory cytokines in the genital tract and CD4+ cell counts in women with acute HIV-1 infection. J Infect Dis, 2008; 198:710–714.
43.
LevinsonP, KaulR, KimaniJ, et al.: Levels of innate immune factors in genital fluids: Association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS, 2009; 23:309–317.
44.
MorrisonC, FichorovaRN, MauckC, et al.: Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion. J Acquir Immune Defic Syndr, 2014; 66:109–117.
45.
RobertsL, PassmoreJA, MlisanaK, et al.: Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J Infect Dis, 2012; 205:194–203.
46.
HeroldBC, KellerMJ, ShiQ, et al.: Plasma and mucosal HIV viral loads are associated with genital tract inflammation in HIV-infected women. J Acquir Immune Defic Syndr, 2013; 63:485–493.
47.
VenkataramanN, ColeAL, SvobodaP, PohlJ, ColeAM: Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol, 2005; 175:7560–7567.
48.
HughesBL, DuttR, RakerC, et al.: The impact of pregnancy on anti-HIV activity of cervicovaginal secretions. Am J Obstet Gynecol, 2016; 215:748.e1–748.e12.
49.
FichorovaRN, DesaiPJ, GibsonFC3rd, GencoCA: Distinct proinflammatory host responses to Neisseria gonorrhoeae infection in immortalized human cervical and vaginal epithelial cells. Infect Immun, 2001; 69:5840–5848.
50.
FichorovaRN, AndersonDJ: Differential expression of immunobiological mediators by immortalized human cervical and vaginal epithelial cells. Biol Reprod, 1999; 60:508–514.
51.
FichorovaRN, LeeY, YamamotoHS, et al.: Endobiont viruses sensed by the human host—beyond conventional antiparasitic therapy. PloS One, 2012; 7:e48418.
52.
IqbalSM, BallTB, LevinsonP, et al.: Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS, 2009; 23:1669–1677.
53.
SoldinOP, GuoT, WeiderpassE, TractenbergRE, Hilakivi-ClarkeL, SoldinSJ: Steroid hormone levels in pregnancy and 1 year postpartum using isotope dilution tandem mass spectrometry. Fertil Steril, 2005; 84:701–710.
54.
ChappellCA, IsaacsCE, XuW, et al.: The effect of menopause on the innate antiviral activity of cervicovaginal lavage. Am J Obstet Gynecol, 2015; 213:204.e1–204.e6.
55.
JaisM, YounesN, ChapmanS, Cu-UvinS, GhoshM: Reduced levels of genital tract immune biomarkers in postmenopausal women: Implications for HIV acquisition. Am J Obstet Gynecol, 2016; 215:324.e1–324.e10.
56.
DezzuttiCS, RichardsonBA, MarrazzoJM, et al.: Mucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial. J Infect Dis, 2012; 206:1931–1935.
57.
DezzuttiCS, UrankerK, BungeKE, Richardson-HarmanN, MacioI, HillierSL: HIV-1 infection of female genital tract tissue for use in prevention studies. J Acquir Immune Defic Syndr, 2013; 63:548–554.
58.
SucklingJ, LethabyA, KennedyR: Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev, 2006:CD001500.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
